Latest Articles

For decades, drug discovery has focused on inhibiting enzymes to treat disease. Yet vast swathes of the proteome remain “undruggable” by traditional approaches. Molecular glues offer a way to remove harmful proteins from cells entirely.

Discover how ABC transporters could offer a targeted approach to tackle drug-resistant bacteria and combat antimicrobial resistance.

For this article, Technology Networks asked a diverse group of academics and industry leaders: How should research funding change to better support innovation? Here’s how current models help – or hinder – their work.

Explore cutting-edge technologies and workflows advancing downstream processing in biopharma, driving purification efficiency and innovation in new therapies.

Presenting at Technology Networks’ Innovations in Disease Modeling 2025 event, Dr. de la Fuente outlined how his lab is using artificial intelligence to reimagine antibiotic discovery – by turning to the human proteome and ancient genomes.

What happens if the US ties drug prices to other nations? Discover how the most-favored-nation policy could shake the global pharmaceutical industry.

Discover how Agilent's AssayMAP Bravo and RapidFire systems accelerate drug discovery with automation and rapid, reliable mass spectrometry.

Nine scientists from academia and industry offer their take on the crucial skills tomorrow’s scientists will need to thrive in an evolving research landscape, from AI to digital lab fluency.

Technology Networks recently had the pleasure of interviewing Dr. Tyler Brown, founder, president and chair of OUTbio San Diego, to learn more about the organization’s origins, rapid growth and mission to create lasting impact.

GLP-1 drugs like semaglutide and tirzepatide show promise in treating obesity, with benefits including weight loss and improved metabolic health. However, concerns about long-term safety, cost, and accessibility remain.